Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Vizimpro (dacomitinib)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Pfizer, SFJ Pharma

Drug class:

pan-HER inhibitor

Related drugs:

‹

›

EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	dacomitinib Sensitive: A1 - Approval dacomitinib Sensitive : A1	dacomitinib Sensitive: A1 - Approval dacomitinib Sensitive : A1
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	dacomitinib Sensitive: A1 - Approval dacomitinib Sensitive : A1	dacomitinib Sensitive: A1 - Approval dacomitinib Sensitive : A1
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	dacomitinib Sensitive: A1 - Approval dacomitinib Sensitive : A1	dacomitinib Sensitive: A1 - Approval dacomitinib Sensitive : A1
EGFR L861Q	Non Small Cell Lung Cancer	EGFR L861Q	Non Small Cell Lung Cancer	dacomitinib Sensitive: A2 - Guideline dacomitinib Sensitive : A2	dacomitinib Sensitive: A2 - Guideline dacomitinib Sensitive : A2
EGFR S768I	Non Small Cell Lung Cancer	EGFR S768I	Non Small Cell Lung Cancer	dacomitinib Sensitive: A2 - Guideline dacomitinib Sensitive : A2	dacomitinib Sensitive: A2 - Guideline dacomitinib Sensitive : A2
EGFR G719X	Non Small Cell Lung Cancer	EGFR G719X	Non Small Cell Lung Cancer	dacomitinib Sensitive: A2 - Guideline dacomitinib Sensitive : A2	dacomitinib Sensitive: A2 - Guideline dacomitinib Sensitive : A2
EGFR G719A	Non Small Cell Lung Cancer	EGFR G719A	Non Small Cell Lung Cancer	dacomitinib Sensitive: C2 – Inclusion Criteria dacomitinib Sensitive : C2	dacomitinib Sensitive: C2 – Inclusion Criteria dacomitinib Sensitive : C2
HER-2 Y772_A775dup	Non Small Cell Lung Cancer	HER-2 Y772_A775dup	Non Small Cell Lung Cancer	dacomitinib Sensitive: C3 – Early Trials dacomitinib Sensitive : C3	dacomitinib Sensitive: C3 – Early Trials dacomitinib Sensitive : C3
HER-2 G778_P780dup	Non Small Cell Lung Cancer	HER-2 G778_P780dup	Non Small Cell Lung Cancer	dacomitinib Sensitive: C3 – Early Trials dacomitinib Sensitive : C3	dacomitinib Sensitive: C3 – Early Trials dacomitinib Sensitive : C3
HER-2 exon 20 insertion	Non Small Cell Lung Cancer	HER-2 exon 20 insertion	Non Small Cell Lung Cancer	dacomitinib Sensitive: C3 – Early Trials dacomitinib Sensitive : C3	dacomitinib Sensitive: C3 – Early Trials dacomitinib Sensitive : C3
HER-2 A775_G776insYVMA	Non Small Cell Lung Cancer	HER-2 A775_G776insYVMA	Non Small Cell Lung Cancer	dacomitinib Sensitive: C3 – Early Trials dacomitinib Sensitive : C3	dacomitinib Sensitive: C3 – Early Trials dacomitinib Sensitive : C3
EGFR A763_Y764insFQEA	Non Small Cell Lung Cancer	EGFR A763_Y764insFQEA	Non Small Cell Lung Cancer	dacomitinib Sensitive: C3 – Early Trials dacomitinib Sensitive : C3	dacomitinib Sensitive: C3 – Early Trials dacomitinib Sensitive : C3